01. Doctor Overview
Dr. Giuseppe Giaccone is a medical oncologist and hematologist at Weill Cornell Medicine. He also resides at NewYork-Presbyterian Hospital as Chief of Thoracic Oncology and is Associate Director for Clinical Research at the Sandra and Edward Meyer Cancer Center. He also directs the phase I clinical trial program for early drug development.
Prior to his roles in New York, Dr. Giaccone practiced as a medical oncologist, hematologist, associate director for clinical research and co-leader of the Experimental Therapeutics Program at the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C. He was also a professor of medical oncology and pharmacology in the Department of Oncology at Georgetown University Medical Center.
Dr. Giaccone’s research includes immunotherapy and other targeted therapy options for the treatment of lung cancer tumors and other malignancies of the chest. He is the principle investigator for various clinical trials at the Research Center and studies genetic abnormalities and drug resistance. Dr. Giaccone is also a co-chair for the American Society for Clinical Oncology’s guidelines for advanced non-small-cell lung cancer.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Oncology
Other Interests & Specialties: Oncology, general oncology, internal medicine, hematology, pharmacology, lung cancer and mesothelioma.
Certifications, Awards & Accolades: Co-chair for the American Society for Clinical Oncology’s guidelines for advanced non-small cell lung cancer, Director’s Award from the National Cancer Institute, New Drug Development Office (NDDO) Honorary Award from the NDDO Foundation, Daniel C. Ihde Memorial Lecture Award from the National Cancer Institute, honorary member of the Hellenic and International Society of Molecular-Genomic Medicine and Research. Hellenic and International Society of Molecular-Genomic Medicine and Research
Education & Experience:
- Medical Degree from the University of Torino Faculty of Medicine
- Fellowship at the National Cancer Institute
- Fellowship at the Universita degli Studi di Torino
- Residency at Universita degli Studi di Torino
- Internship at Universita degli Studi di Torino
30 Immunotherapy in advanced NSCLC-from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open. May 2018;3(4):e000298 doi: 10.1136/esmoopen-2017-000298
Biology and management of malignant pleural mesothelioma. European Journal of Cancer. November 2006;42(16):2706-2714. doi: 10.1016/j.ejca.2006.07.011
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. Journal of Clinical Oncology. March 2006;24(9):1435-42. doi: 10.1200/JCO.2005.03.3027
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clinical Cancer Research. February 2002;8(2):596-606.
04. Mesothelioma Clinical Trials
Mesothelioma Clinical Trials by Giuseppe Giaccone, M.D.
Dr. Giuseppe Giaccone is associated with the following clinical trials:
Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
Last Updated: July 17, 2012